Welcome to our dedicated page for Amphastar Pharmaceuticals news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharmaceuticals stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Established in 1996, Amphastar is known for developing, manufacturing, and marketing injectable and inhalation products using state-of-the-art, cGMP-compliant facilities. The company operates five manufacturing facilities across the United States, China, and Europe, along with a cutting-edge new drug research center.
Amphastar's core business revolves around producing approximately 15 injectable products, with a strong focus on both generic and branded drugs that target large markets with high technical barriers to entry. The company's comprehensive portfolio includes injectable, inhalation, and intranasal products, catering to hospitals and urgent care clinical settings. These products are distributed through group purchasing organizations and drug wholesalers, with the majority of revenue being generated in the United States.
The company leverages its longstanding relationships with major group purchasing organizations and drug wholesalers in the U.S. to establish significant market share quickly. Amphastar's finished pharmaceutical products and Active Pharmaceutical Ingredient (API) products are divided into two main segments: Finished Pharmaceutical Products and API Products.
Recent achievements for Amphastar include the acquisition of commercially successful products like BAQSIMI® and the strategic expansion of their diabetes portfolio. The company reported impressive financial results for the third quarter of 2023, with net revenues of $180.6 million and a GAAP net income of $49.2 million. The strong performance was driven by their diabetes portfolio and the newly acquired BAQSIMI®.
Amphastar's product development pipeline is robust, with multiple ANDAs and biosimilar products targeting significant market opportunities. The company also announced the FDA approval of Albuterol Sulfate Inhalation Aerosol, marking a milestone in their ability to develop complex generic inhalation products. This approval reflects Amphastar’s technological and manufacturing expertise, positioning the company for future growth.
Amphastar's commitment to quality and innovation is further demonstrated by their strategic acquisition and integration activities, focused on maximizing commercial potential and delivering high-quality pharmaceutical solutions. The company continues to enhance its pipeline with both generic and proprietary products, targeting products with large market sizes and high growth potential.
For more information, visit www.amphastar.com.
BetterInvesting Magazine has announced Amphastar Pharmaceuticals (NASDAQ: AMPH) as its 'Stock to Study' and Medtronic (NYSE: MDT) as its 'Undervalued Stock' for the September 2024 issue. The National Association of Investors Corp. (NAIC) encourages investors to focus on fundamentals and informed decision-making. The magazine's choices are informational and educational, not endorsements. A trial version of BetterInvesting's tools is available for non-members to analyze these stocks. The committee includes several CFA members who review the stocks, emphasizing investor education. Full details will be available in the magazine's September issue.
Amphastar Pharmaceuticals (NASDAQ: AMPH) has announced a $50 million increase to its share buyback program, effective from June 3, 2024. This initiative aims to counterbalance a dilution caused by the company's equity compensation programs. The repurchases will be made through various means, including open market and private block transactions. The company currently has three ANDAs filed with the FDA, targeting a market size of over $1.4 billion, and is developing three biosimilar products with a market size of over $7 billion and four generic products targeting over $3 billion. Amphastar's subsidiary in China, ANP, has multiple DMFs filed with the FDA and is developing additional DMFs. Amphastar primarily focuses on developing and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products, along with insulin API products.
Amphastar Pharmaceuticals announced that its CFO, Bill Peters, and EVP of Corporate Administration, Jacob Liawatidewi, will participate in a fireside chat at the Jefferies Global Healthcare Conference. This event is scheduled for June 6, 2024, at 12:30 pm EST. The discussion will be moderated by an analyst and focus on the company's strategic initiatives and financial outlook. Investors can access the webcast through Amphastar's website, which will be available for 30 days following the presentation.
Amphastar Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol. This product treats and prevents bronchospasm in patients aged four and older and is bioequivalent to Teva's ProAir® HFA. Amphastar plans to launch the product in Q3 2024. The U.S. market for branded and generic albuterol sulfate inhalation aerosols was approximately $1.7 billion as of March 2024. Amphastar also has three ANDAs, three biosimilar products, and four generic products in development, targeting markets worth over $11.4 billion. The approval underscores Amphastar’s manufacturing capabilities and commitment to developing complex inhalation products.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will have Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, join an Analyst-Moderated fireside chat at the Bank of America Health Care Conference on May 15th, 2024. The webcast will be accessible for 30 days on Amphastar's Pharmaceuticals website.
Amphastar Pharmaceuticals reported net revenues of $171.8 million for the three months ended March 31, 2024. The company achieved GAAP net income of $43.2 million and adjusted non-GAAP net income of $55.3 million. Notable highlights include BAQSIMI revenue growth of 22% over the first quarter of 2023. The company experienced positive sales increases in several key products like Glucagon, Epinephrine, and Primatene MIST ®. However, there were decreases in sales of Lidocaine, Enoxaparin, and Naloxone. The company's gross profit margin was 52.4% of net revenues, driven by factors like increased sales of higher-margin products. Amphastar's financial performance demonstrates a strong first quarter with promising growth potential.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will release its first quarter earnings for 2024 on May 8, 2024. The company focuses on developing, manufacturing, and selling generic and proprietary injectable, inhalation, and intranasal products. They also sell insulin API products primarily used in hospital settings. The conference call to discuss financial results will be held at 2:00 p.m. Pacific Time.
FAQ
What does Amphastar Pharmaceuticals, Inc. specialize in?
Where are Amphastar’s manufacturing facilities located?
What are Amphastar’s main product segments?
What recent product approval has Amphastar received from the FDA?
How does Amphastar distribute its products?
What significant acquisition has Amphastar completed recently?
What are the financial highlights for Amphastar’s third quarter of 2023?
What is the focus of Amphastar’s product development pipeline?
Where can I find more information about Amphastar Pharmaceuticals?
What are some key products in Amphastar’s portfolio?
